Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat Mesilate vs Heparin for ECMO Anticoagulation
NCT06276010Recruiting
- Start
- Jul 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Nafabelltan in thrombosis (2 arms). Primary endpoint: Incidence of thrombotic complications at 7 days. Started Jul 2024; status: recruiting.
02
Drugs
Nafabelltan
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT06276010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06276010.